There are major challenges with intrinsic and acquired resistance to BRAF inhibitors [8, 11], and use of BRAF inhibitors may cause paradoxical activation of the MAPK pathway, leading to increased tumour growth [12, 13]. The gene discussed is BRAF; the disease is neoplasm.